Die Inhalte stammen aus dem NEJM Journal Watch Oncology & Hematology, der von der NEJM Group, a Division of the Massachusetts Medical Society, hergestellt und veröffentlich wird. Alle Rechte sind vorbehalten und alle Inhalte sind urheberrechtlich geschützt. Universimed und unsere Sponsoren ermöglichen Ihnen den Zugang zu diesen Inhalten als professionelle Unterstützung.
Managing Splanchnic Vein Thrombosis
Anticoagulant therapy was safe and effective in patients with SVT.
Reduced-Intensity Chemotherapy for Lower-Risk Myelodysplastic Syndromes
Decitabine showed improved responses compared with azacitidine when each was given only on the first 3 days treatment cycle.
Teclistamab for Relapsed or Refractory Multiple Myeloma
The bispecific therapeutic monoclonal antibody led to partial or better responses in a high proportion of patients with heavily pretreated myeloma.
Do Abiraterone or Enzalutamide Increase Risk for Metabolic and Cardiovascular Events?
Both agents were associated with increased risk for major events, but only abiraterone was associated with increased risk for minor events.
Pembrolizumab plus Chemotherapy Improves Survival in Triple-Negative Breast Cancer
Final analysis of KEYNOTE-355 shows significant improvement in overall survival with the addition of pembrolizumab in patients with CPS ≥10.
Low-Molecular-Weight Heparin Outperforms Other Options for Inpatient VTE Prophylaxis
A meta-analysis supports current guidelines and demonstrates that LMWH balances benefits and risks better than unfractionated heparin or direct-acting oral anticoagulants.
Radiotherapy Does Not Improve Outcome in Borderline Resectable Pancreatic Cancer
Overall survival at 18 months with neoadjuvant FOLFIRINOX exceeded historical rates, but radiotherapy did not provide additional benefit.
Cabozantinib/Atezolizumab Improves Progression-Free Survival in Hepatocellular Carcinoma
However, there was no difference in overall survival.
Oncolytic Viral Injections Tested in Pediatric Diffuse Intrinsic Pontine Glioma
A phase I trial of oncolytic virus in childhood brain cancer shows tolerable safety.